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Electrospray ionization mass spectrometry has been used to investigate the complex 
formation between a double-stranded oligonucleotide and various antitumor drugs belonging 
to two categories: intercalators (ethidium bromide, amsacrine and ascididemin) and minor 
groove binders (Hoechst 33258, netropsin, distamycin A, berenil and DAPI). The goal of this 
study is to determine whether the relative intensities in the mass spectra reflect the relative 
abundances of the species in the solution phase. The full scan MS spectra suggest non-specific 
binding for the intercalators and specific binding for the minor groove binders. The 
preferential stoichiometries adopted by each minor groove binder have been determined by 
studying the influence of the drug concentration on the spectra. We obtained 2:1 > 1:1 for 
distamycin, 1:1 > 2:1 for Hoechst 33258 and DAPI, and only the 1:1 complex for netropsin 
and berenil. These features reflect their known behavior in solution. The compared MS/MS 
spectra of the 1:1 complexes with Hoechst and netropsin, when correlated to published 
crystallographic data, suggest the possibility to infer some structural information. The relative 
binding affinities of the drug for the considered duplex have been deduced with two by two 
competition experiments, assuming that the relative intensities reflect the composition of the 
solution phase. The obtained affinity scale is the following: netropsin > distamycin A > DAPI 
> Hoechst 33258 > berenil. These examples show some of the potential uses of mass 
spectrometry as a useful tool for the characterization of specific drug binding to DNA, and 















Mass spectrometry measurements on large molecules have been widely exploited since 
the introduction of electrospray ionization (ESI)1,2 and matrix-assisted laser 
desorption/ionization (MALDI)3,4 for the investigation of their primary structure by 
interpretation of the fragmentation patterns. Electrospray ionization, which is a soft ionization 
method (the analyte can be given little internal energy during the transfer to the gas phase), 
has furthermore opened the door to investigation of higher-order structures of molecules of 
biochemical interest5-7. The wide potentialities of mass spectrometry have been pushed to 
good use in protein research, from primary to quaternary structure8-12. 
Nucleic acids have been far less investigated than proteins to date, but the interest in this 
field keeps growing (see refs. 13, 14, and references therein). Mass spectrometry has been 
used for primary structure determinations of oligonucleotides15,16 and for detection of high-
mass DNA samples17. The first observations of noncovalent duplex structures date back to 
199318-21 and the specificity of their formation has been discussed in 1995 by Ding and 
Anderegg22. In 1997, small model oligonucleotide duplexes have been investigated by 
Williams et al. by the BIRD method23: they correlated the stability of the duplexes in the gas 
phase with the number of hydrogen bonds between the strands, thereby inferring that the 
solution structure is in that respect maintained in the gas phase. Noncovalent interactions of 
molecules with the genetic material have also been investigated by electrospray ionization 
mass spectrometry: observation of interaction between small drug molecules and single 
strands24, hairpin DNA25 or oligonucleotide duplex26-28, interaction between proteins and 
oligonucleotides29,30 have been reported. 
The study described herein is in keeping with the general pattern of determining the 
experimental conditions and the nature of molecules for which the informations obtainable 
with mass spectrometry are useful to solve problems relative to the solution phase behavior. 
There are two ways to consider that problem. First, one should determine the conditions in 
which, when recording a full scan MS spectrum, the nature of the species detected and their 
relative intensities reflect those in solution. This would allow the determination of the 
stoechiometries of the complexes and the binding constants in solution. Second, the 
manipulation of the complexes in the gas phase by MS/MS experiments allows the 
determination of energetic parameters, such as binding energies, in the gas phase. This feature 
could be particularly important in the case of multiple associations, where different 
contributions are difficult to sort out by solution phase measurements. It is also a probe of the 
supramolecular interaction in the absence of solvent that would lead to a better understanding 
of the solvent effect. 
Oligonucleotide duplexes and their complexes with small molecules have been chosen 
as a model system. The comparison was performed between full scan spectra and what is 
known to be present in solution. The studied ligands belong to two classes of drugs: minor 
groove binders and intercalators. The common characteristics of minor groove binders are a 
flat, crescent shape, at least one positive charge, and many donor or acceptor groups. These 
features allow them to fit tightly in the minor groove of the double helix of DNA31,32. The 
complementarity between the acceptor/donor groups of the floor of the minor groove and the 
drug is at the heart of sequence recognition by synthetic molecules33. The studied ligands 
(scheme 1) have a higher affinity for regions with at least four consecutive A or T bases. 
Intercalator molecules, however, have a flat aromatic part which is able to stack between the 
base pairs of the duplex. Their binding to DNA is non-specific, with at the least a preference 
for GC-rich regions34,35. All of these drugs have either a well-established or a potential 
antitumor activity that is partially related to their binding to DNA. A very special effort is 
made nowadays in drug design to improve the sequence specificity of minor groove binders, 
with the final goal of targeting specific genes33,36-38. Structural characterization of the 
complexes are generally made by crystallography39, NMR40 or electric linear dichroism41, 
which are quite labour-intensive methods. Their thermodynamic characterization is usually 
performed by UV/visible spectrophotometry, NMR or fluorescence titrations42,43, or more 
recently by microcalorimetric methods44,45.  In this article we will show which kind of 
informations can be readily extracted from mass spectrometry measurements, and their utility 





Oligonucleotide single strands were chosen purposely non self-complementary and of 
significantly different masses to allow unambiguous interpretation of the spectra. Single 
strand d(GGGGATATGGGG) will be referred to as G (monoisotopic mass = 3804.67) and 
the complementary strand d(CCCCATATCCCC) will be called C (monoisotopic mass = 
3484.62). The resulting duplex (which will be called GC) is an analog of the well-studied 
self-complementary Dickerson dodecamer d(CGCGAATTCGCG)246-49. All oligonucleotides 
were purchased from Eurogentec (Sart-Tilman, Belgium). 
Minor groove binders (see scheme 1 for the structures and the monoisotopic masses) 
include Hoechst 33258 (Acros, Geel, Belgium), netropsin, distamycin A (Serva, Heidelberg, 
Germany) and berenil (kindly provided by C. Bailly (INSERM, Lille, France). Intercalators 
(scheme 2) are ethidium bromide, amsacrine (Sigma, Bornem, Belgium) and ascididemin 




Oligonucleotides were diluted with freshly prepared NH4Ac solution, mixed in 
equimolar proportions, annealed at 80°C and slowly cooled to room temperature to allow the 
formation of the duplex. Desalting was performed three times (or more when the necessity 
was revealed by the spectra) with Microcon® filters (Amicon, Beverly, MA, USA) with a 
3000 Da cut-off. The resulting duplex stock solution was 100 µM in 50 mM or 100 mM 
NH4Ac (following the mass spectrometer, see below). 
The electrolyte ammonium acetate has been chosen in agreement with the published 
literature. To determine its suitable concentration, we proceeded to thermal denaturation of 
the duplex in various NH4Ac concentrations. The concentration 50 mM has been chosen for it 
stabilizes the duplex. For a 2 μM solution in duplex, Tm is higher, 48°C,  in a 50 mM NH4Ac 
as compared to a 10 mM solution, 37°C (figure 3 ). Circular dichroism measurements (data 
not shown) proved that in such conditions, although different than usual NaCl solutions 
traditionally used to study nucleic acids, the double helix is in a regular B-DNA form. In 
addition, ammonium acetate concentrations above 10 mM have been previously shown to 
reduce single strand’s charge states50 , an interesting property because the lower the charge 
state, the lower the coulombic repulsion between the strands, and thus the more stable the 
complex.  
Minor groove binders stock solutions were prepared by diluting the weighted solid in a 
NH4Ac solution of appropriate concentration. Intercalators were dissolved in methanol to a 




Thermal denaturations were performed on a UV spectrophotometer Lambda 5 (Perkin 
Elmer, Norwalk, CT, USA) interfaced with a PC XT for data acquisition. The quartz cells 




Experiments were carried through with two different instruments. A Finnigan LCQ 
(ThermoQuest, Bremen, Germany) was used for full scan MS experiments. A Q-TOF 
(Micromass, Manchester, UK) was accessible when a resolution above 1,000 was required 
(competition experiments with drugs differing by only some daltons). In MS/MS experiments, 
the control of the collision energy was found easier with a quadrupole-TOF as compared to 
the LCQ.   
With the LCQ, duplex solutions in 20/80 (v/v) methanol/100 mM NH4Ac electrolyte 
were electrosprayed in the negative mode. Methanol was necessary to obtain a good spray, 
and circular dichroism revealed that 20 % methanol did not alter the B double helix structure. 
The electrospray source conditions were optimized to favor the observation of the fragile 
noncovalent species. This implies that the ions should have undergone just enough collisions 
in the high-pressure region of the source to be fully desolvated, keeping their internal energy 
low enough not to be destroyed. We found that, when applying a heated capillary temperature 
of 190°C, the complexes were intact and fully desolvated, so that a capillary-skimmer voltage 
of only few volts was sufficient to transfer the ions in the lower pressure region. Although 
complexes survive to cone voltages up to -50 V, we used a constant value of –6 V to have a 
higher signal to noise ratio. The scanned mass range (1,000-2,000) was also kept constant in 
every experiment. For competition experiments, the considered species are in the range 
[1450-1550], so that no significant effect on the intensities due to the qz values is suspected. 
The absence of discrimination was checked by comparing LCQ and Q-TOF results. 
With the Q-TOF, the Z-Spray source was used to allow the analysis of duplex solutions 
in 50 mM NH4Ac without addition of methanol. The experimental conditions were optimized 
for the Z-Spray (a totally different source geomerty) with the same principles in mind : a 
source block temperature of 80°C and a cone voltage of 50 V were used (higher charge states 
could be additionnaly obtained under softer conditions, but the incomplete desolvation 
resulted in a noisy spectra, see below).  
The DNA concentration has been optimized to 10 µM. It was observed that the 
duplex/single strands ratio rises when diluting the sample. However, the signal is decreasing 
subsequently and the spectra become more noisy. An even more interesting feature of the 
dilution experiment is the partial suppression of sodium adducts when the duplex 
concentration is lower or equal to 10 μM (see the insets of figure 1). This indicates that the 
Na+ counterions are displaced by NH4+, and that a [NH4+]/[duplex] ratio of at least 5,000 is 
preferable. Ammonium adducts are readily eliminated by NH3 loss during desolvation, which 
simplifies the spectra. 
 
 
Results and Discussion 
 
Specificity of Duplex Formation 
 
The characteristics that allow to differentiate the specific associations observed by 
electrospray from non-specific ones have been discussed by Smith and Light-Wahl51: these 
include persistence upon dilution, stability in the gas phase, and sensitivity to solution 
modifications. For double-stranded DNA, non-specific aggregation is reflected in random 
associations of non-complementary strands. These non-specific aggregations are often due to 
concentration effects. Ding and Anderegg22 have demonstrated that they were avoidable by 
working at low concentration (around 10 μM) with reasonably long strands (octamers). This 
is confirmed by our study of the effect of the concentration : the non-specific homodimers 
(GG)5- and (CC)5- that were still present at very low intensity at 25 μM concentration (fig. 1-
top) completely disappeared at 10 μM concentration (fig. 1-center), while the relative 
intensity of the specific duplex increased compared to the single strands. 
The gas phase stability of the duplex has been probed by MS/MS on different charge 
states (Fig. 2). A capillary-skimmer voltage of 30 V (instead of 50) was chosen to maintain 
intact the (GC)6- species for its selection in MS/MS. As expected, the collision energy 
necessary to fragment 50% of the duplex depends on the charge state. The adequate 
acceleration voltage applied before entering the quadrupolar collision cell varied from 19 V 
for (GC)6- to 25 V for (GC)5-, in agreement with the higher stability of lower charge states. 
The discrepancy between the absolute values of the different voltages used is only apparent: 
the voltage on the sampling cone, on the contrary to the voltage used for CAD, cannot be 
translated in terms of kinetic energy of the ions. In fact, in the source, the voltage on the cone 
induces the drag of the ions through the atmospheric pressure gas where multiple collisions 
occurs at low energy. This activation process is referred to as slow heating52. The fragments 
resulting are the single strands, between which the available charges are shared. In addition, 
strand G has a greater tendency to leave protons to the other strand, therefore resulting in 
higher charge states than strand C. This is in agreement with the lower pKa value for guanine 
than cytosine (2.1 vs 4.2). The relatively high values of the collision energy necessary to 
fragment the duplex (single strands are already fragmenting to a significant extent at 30 V, 
data not shown) are indicative of the specificity of the analyzed complex. Indeed, non-specific 
complexes resulting from random aggregation in the gas phase are typically weak, and are 
readily fragmented at low collision energies. 
To show how closely the mass spectra can be an image of the species present in the 
sprayed solution, we compared a freshly annealed solution in 50 mM NH4Ac with a solution 
left overnight at 37°C in a 10 mM NH4Ac solution (Tm = 38°C), sprayed immediately without 
cooling. In this solution, there should be approximately half the amount of duplex than in the 
freshly annealed one (see fig. 3). The MS results (fig. 4) show that the relative intensity of the 
duplex compared to the single strands is indeed reduced by a factor of about two in the 
partially denatured sample. This observation strongly supports that the relative intensities of 
the noncovalent duplex peaks observed in the gas phase closely reflect the composition of the 
solution. The increase of sodium adducts in the latter spectrum indicates again that lower 
NH4Ac concentrations (10 mM instead of 50 mM) do not efficiently displace the sodium from 
the negatively charged ions in solution as mentionned above.  
 
Complexes with Minor Groove Binders 
 
Stoichiometry - Once having set up the optimal conditions for the observation of the 
specific duplex, they were used for the study of the non-covalent interactions between the 
duplex and the minor groove binders displayed in scheme 1. Figure 5 shows the spectra 
obtained with the LCQ for the 1/1 drug-duplex mixtures. Different behaviors can be 
distinguished for the different drugs following their spectra. Berenil and netropsin show 
exclusively the 1:1 complex, DAPI and Hoechst 33258 show a small amount of 1:2 complex 
in addition to the 1:1 one, and for distamycin A the 1:2 complex is the predominant species.  
To further characterize the formation of the 1:1 and 1:2 complexes, we studied the 
influence of the concentration of drug, from 2 µM to 20 µM, added to the 10 µM duplex 
solution in the case of netropsin, Hoechst 33258 and distamycin A. The data are summarized 
in figure 6, where the relative intensities have been normalized to 100 % for each spectra. For 
netropsin, no 1:2 complex could be observed, even at the highest drug concentrations. For 
distamycin A, the 1:2 complex becomes rapidly predominant as the drug concentration 
increases, thereby indicating the preferential one-step formation of this 1:2 complex over the 
1:1 complex, whose signal vanishes progressively. The distinct behaviors of netropsin and 
distamycin A are well-known in the solution phase31. Distamycin forms a head-to-tail dimer 
which inserts in the AT-rich region, thereby widening the minor groove53-54. This 1:2 binding 
mode is favored by an alternating AT sequence compared to poly(A)-type ones because they 
naturally present a wider and more flexible minor groove31,55. In the case of netropsin, 
however, the positive charges present at each end of the molecule prevent the formation of 
such dimers and the resulting complex with the AT-rich region is thus exclusively 1:1.  
In the case of Hoechst 33258, mass spectrometry is shedding a new light on a 
controversial problem: the possible existence of multiple stoichiometries for Hoechst binding 
to DNA56-58. With measurements in solution, in general, the presence of minor species of 
different stoichiometries is only suggested by clues. For example, a fluorescence 
measurement that cannot be fitted with a 1:1 model may be indicative that other complex 
species are present, but no clear cut can be made because the contributions of the different 
complexes to the total fluorescence can’t be separated. Our results suggest the formation of a 
1:2 complex with a lower binding constant than for the 1:1 complex, which is the 
predominant one. Mass spectrometry has the advantage of direct assignment of the 
stoichiometry, but it can also give an indication about the relative amounts of the different 
species. In this way of thinking, we are assuming that the relative intensities observed by ESI-
MS reflect the relative abundances in solution. This argument has been used in various 
studies59-62 and is thought to be valuable when the observed complexes are likely to be 
stabilized in the gas phase compared to the solution phase, mainly by electrostatic and 
hydrogen bonding interactions63-64. This is indeed the case for the binding of minor groove 
ligands with double-stranded DNA. 
 
Competition experiments - With the same way of reasoning, competition experiments 
were undertaken: the duplex was mixed with equal amounts of two drugs in a 10-10-10 µM 
solution, and the spectra of the mixtures were recorded. Some are reported in figure 7. The 
competition experiments performed on the LCQ were made for drugs of significantly 
different masses. The competition between Hoechst 33258 and netropsin required the 
resolution of the Q-TOF. These competition experiments allow the easy determination of 
which drug among the two ones tested binds the duplex preferentially. For example, it is 
readily inferred from spectrum (b) that berenil has approximately the same binding affinity as 
Hoechst 33258, and from (a) that DAPI binds the duplex with higher affinity. We can 
therefore step by step establish a relative affinity scale of drugs for a given duplex. In our 
case, we obtained the following scale: netropsin > distamycin A > DAPI > Hoechst 33258 > 
berenil. Thermal denaturation experiments showed that the complex with netropsin is indeed 
more stable than the one with Hoechst 33258 (fig. 8): the more stable the complex, the higher 
the denaturation temperature65. This possibility opens the door to many useful applications in 
the field of drug design, but some work is still needed to lead to quantitative measurements, 
with the support of microcalorimetric data. The improvement brought by a selected 
modification of a drug can be tested by mass spectrometry by a competition experiment 
between the modified molecule and the original one.  
 
MS/MS - To investigate the gas phase structure and stability of the (1:1) complexes, we 
performed MS/MS experiments on the (GC+drug)5- species for Hoechst and netropsin (fig. 9). 
As the comparisons were made between the duplex and the different complexes only one 
charge state was monitored. The 5- charge state was chosen for MS/MS experiments, as 
allowing a suitable collision voltage range. The effect of the charge state on the MS/MS 
behavior is under investigation as it can probe the coulombic contribution of the interaction. 
The CID of the complexes in the 5- charge state shows a different behavior following the 
studied drug. The complex (GC+Hoechst)5- dissociates at 30 eV into the duplex and the single 
strands, with release of the neutral drug. The complex with netropsin (GC+Net)5-, however, 
dissociates at the same collision energy into the single strands with the netropsin drug 
remaining attached on strand G. The magnitude of the collision energy needed to fragment the 
(GC+drug)5- complexes reveals that they are more stable than the duplex alone. This parallels 
the feature, well-known in the solution phase, that minor groove binders stabilizes the double 
helix structure by hydrogen and Van der Waals bonding to both strands66. 
Furthermore, could the different dissociation channel reflect structural features of the 
drug binding to this particular dodecamer? Part of the answer has been found in 
crystallographic structures of similar complexes. Netropsin and Hoechst are known to bind to 
the minor groove in the AT rich regions of the DNA31-33, and therefore in the ATAT region of 
our dodecamer. Crystallographic structures of the complexes between the self-complementary 
dodecamer d(CGCGATATCGCG)2 and netropsin67 or Hoechst68 have been published and 
hydrogen bond number and lengths have been calculated (fig. 10). Hoechst forms three 
hydrogen bonds involving NH···O interactions (whom one is tight : 2.9 Å) plus one weak 
CH2···O interaction with the duplex. In contrast, netropsin has four NH···O or NH···N 
hydrogen bonds with the duplex, whom one is very tight (2.6 Å). This simple count of the 
hydrogen bonds in the crystallographic structure of an analog dodecamer with the same 
binding region (ATAT) provides an explanation for the relative stabilities of the two 
complexes: complex with netropsin is more stable than complex with Hoechst because it 
forms more hydrogen bonds with the duplex. The difference in the fragmentation behavior of 
the two (GC+drug)5- species can also be explained the same way: the balance of the number 
of hydrogen bonds with the two strands is more equilibrated in the case of Hoechst (2-1) than 
in the case of netropsin (3-1). Netropsin has therefore a greater tendency to remain attached to 
one of the strands when fragmentation occurs in the gas phase. These results show the 
potentiality, well worth to be further investigated, that fragmentation patterns upon CID could 
reflect structural features of the noncovalent bonding between molecules. 
 
Complexes with Intercalators 
 
Stoichiometry - The complexes between the three ligands displayed in scheme 2 and the 
duplex have been investigated by ESI-MS on the ion trap instrument. Figure 11 shows the 
spectra recorded for the three drugs at 10 µM and 30 µM concentration, the duplex 
concentration being 10 µM. The spectra reveal a different binding mode than minor groove 
binders: instead of well-defined stoichiometries, the intercalators show multiple associations 
with a distribution suggesting a non-specific behavior, which is compatible with their 
behavior in solution. The relative intensities complexes/duplex for the different drugs 
parallels their polarity: peaks from complexes with the positively charged ethidium are far 
more intense than those with the polar amsacrine, which are in turn more intense than those 
with the quasi non-polar ascididemin molecule. This could be an artifact due to the 
electrospray process itself. Either the complexes are formed during the electrospray process, 
and this complex formation is favored with more polar molecules when the dielectric constant 
diminishes ; or the complex is destructed in the gas phase, the less polar the ligand, the less 
stabilized the complex when the solvent contribution is absent. Solution binding constants 
will be required to drive our interpretation, but these results indicate that in the case of 
intercalators, the intensities of the peaks may not reflect the abundances in solution, but other 
characteristics of the drug, like its polarity. 
 
Displacement of ethidium by minor groove binders - The concept of competition 
experiments has been applied to ethidium bromide: a duplex-ethidium 10 µM-15 µM mixture 
has been allowed to react with various amounts (0 to 15 µM) of minor groove binder at least 5 
minutes (which turned out to be the minimum time to establish the equilibrium). Analog 
measurements are routinely achieved in the solution phase to determine the binding constant 
of the minor groove binder, provided that ethidium’s one is known. The titration of the 
complex with ethidium by the other drug is monitored by fluorescence spectroscopy69-70. This 
experiment has been achieved with Hoechst 33258 and netropsin, to check for a further 
confirmation of the greater affinity of netropsin to our duplex: netropsin should then replace 
the ethidium molecules more readily than Hoechst 33258. The results displayed in figure 12 
show that this is indeed the case. The (duplex + netropsin + n ethidium) series is taking more 
readily the precedence over the (duplex + n ethidium) series than does the (duplex + Hoechst 
+ n ethidium) one. Furthermore, an observed contribution of the series (duplex + 2 Hoechst + 
n ethidium) at highest Hoechst concentrations (data not shown for clarity of the figure) is in 
agreement with the observation of the 2:1 complex noted above. The fact that the duplex is 
bound to intercalators and minor groove binders at the same time is compatible with the 
preference of the former for GC regions and of the latter for the ATAT site, but we cannot 
either rule out the possibility of non-specific aggregation of ethidium on the (duplex + minor 
groove binder) complex during the electrospray process. 
Conclusion 
 
Our study of the non-covalent interaction between duplex DNA and various drugs has 
demonstrated the ability of mass spectrometry to distinguish between the specific and non-
specific interactions present in the solution phase. The potential uses of mass spectrometry as 
a rapid drug screening method has been revealed by our study of minor groove complexes. 
First, the stoechiometry of the complex(es) present in solution is readily assigned in a single 
experiment. Second, relative affinities for a particular sequence can be deduced by 
competition experiments with a small amount of material. If validated with a wider panel of 
drugs, such a protocol could be used as a support tool for drug design by the direct 
comparison of a modified molecule to its original form to qualitatively determine the 
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Legends to Schemes and Figures 
 
Scheme 1   
Chemical structure of DNA minor groove binders 
 
Scheme 2 
Chemical structure of DNA intercalating agents 
 
Figure 1 
ESI spectra of duplex solutions recorded with Q-TOF at different duplex concentrations, all in 
aqueous 50 mM NH4Ac (no organic solvent added). The single strands are noted C and G and 
(GC) is the specific duplex. The zoom on the (GC)5- species shows the distribution of sodium 




CID spectra on (a) the duplex (GC)5- at 25 V  energy before entering the quadrupole and (b) 
the duplex (GC)6- at 30 V. The single strands are noted C and G. 
 
Figure 3 
Thermal denaturation curves of the duplex in 10 mM NH4Ac (ò) and in 50 mM NH4Ac (è). 
The inflection points (Tm) are located at 35°C and 48°C respectively. The absorbance values 
have been normalized to allow a visual comparison of the curves. 
 
Figure 4 
Compared full scan Q-TOF spectra of a freshly prepared 10 µM duplex solution in 50 mM 
NH4Ac (a) and a 10 µM solution partially denatured for 12 hours at 35°C in 10 mM NH4Ac 
(b). The conventions are the same as in previous figures. 
 
Figure 5 
Full scan ESI-ion trap spectra of equimolar (10-10 µM) duplex-drug mixtures. Drugs are (a) 
netropsin, (b) berenil, (c) Hoechst 33258, (d) DAPI and (e) Distamycin A. 
Figure 6 
Plots of the relative intensities of the different species versus the drug molar fraction added to 
a 10 µM duplex solution for (a) netropsin, (b) Hoechst 33258 and (c) distamycin A. The filled 
circles (l) represent the intensity of the duplex (sum of the 5- and 4- charge states), the filled 
squares (n) represent the intensity of the 1:1 complex (sum of the 5- and 4- charge state) and 
the filled triangles (t) represent the 1:2 complex (5- charge state only, due to the limited mass 
range). The dots are bonded by a guideline. Spectra were recorded with the LCQ. 
 
Figure 7 
Simple ESI spectra of equimolar (10-10-10 µM) mixtures of the duplex and two drugs which 
are thus in competition for binding to the DNA. Drug pairs are (a) DAPI/Hoechst, (b) 
berenil/Hoechst, (c) DAPI/netropsin and (d) Hoechst/netropsin. The latter has been recorded 
with the Q-TOF, while the formers with the LCQ, with a constant mass range of [1,000-
2,000] (only a portion of the spectra is shown, for the clarity of the figure). 
 
Figure 8 
Thermal denaturation curves of the duplex (l), its complex with Hoechst 33258 (t) and 
netropsin (n). All solutions were in 50 mM NH4Ac. The absorbance values have been 
normalized to allow a visual comparison of the curves. 
 
Figure 9 
CID spectra on the (duplex + Hoechst)5- (top) and (duplex + netropsin)5- (bottom) species, 
both recorded at 30 eV acceleration energy (laboratory frame). 
 
Figure 10 
Drawings illustrating the interactions between Hoechst 33258 (left) and netropsin (right) with 
the self-complementary d(CGCGATATCGCG)2 dodecamer. The hydrogen bonding 
interactions between the drug and the dodecamers are shown by dotted lines. 
(Crystallographic data reproduced from ref 68: M. A. A. F. de CT Carrondo et al., 
Biochemistry, 28, 7849 (1989)). 
 
Figure 11 
Full scan ESI-ion trap spectra of duplex + intercalator mixtures. The duplex concentration 
was kept at 10 µM. The nature of the intercalator and its concentration are noted in the top left 
hand corner of each spectrum. The stoechiometries of the observed species are noted (GC+n), 
n being the number of added intercalator molecules. 
 
Figure 12 
Full scan ESI-ion trap spectra of the competition experiments between ethidium and netropsin 
(left) or Hoechst (right) at different minor groove binder molar fractions (noted in the top left 
hand corner of each spectra). The series are labeled as following: à for the lone duplex, æ for 
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